Making Medicines: The Journey from CRISPR Technology into CRISPR Medicines
What if you could repair broken genes?
The gene-editing technology known as CRISPR burst onto the scientific scene in 2012 and has been profoundly transforming biological research ever since. CRISPR has also captured the public’s attention and imagination, as medicines that once seemed like science fiction may now be within our grasp. But translating a tool of basic research into medicines is not easy. Katrine Bosley is the CEO of Editas Medicine, a biotech company working on making the medicines of the future for people living with devastating diseases—many without any other treatment options. She will share with us the progress the team at Editas Medicine has made over the past four years and what’s next as Editas begins human clinical trials with their first experimental medicine for a rare, genetic form of childhood blindness.
- 11:30 a.m.
- 12:15 p.m.
- 1:00 p.m.
Ralph Connor Memorial Lecture
About the Speaker
Katrine Bosley is the chief executive officer of Editas Medicine and has been part of the biotechnology industry for more than 25 years. Through her career she has led such innovative organizations as Avila Therapeutics and Adnexus Therapeutics and worked to advance innovative products and technologies (Tysabri [natalizumab], covalent drugs, genome editing). Bosley has also worked as entrepreneur-in-residence at the Broad Institute and in acquisitions, initial public offerings, business development and licensing, commercial operations, portfolio strategy, and venture capital. She has led a wide range of transactions (financings, acquisitions, alliances) with an aggregate realized value of over $3 billion and total potential value exceeding $10 billion.
Bosley has been recognized as one of the 100 Most Creative People in Business by Fast Company (2016), one of 30 Global Game Changers by Forbes (2016), Entrepreneur of the Year by the New England Venture Capital Association (2013), and one of the Top Ten Women in Biotech by FierceBiotech (2010).
In addition to her role at Editas, Bosley currently serves as chair of the board of Genocea Biosciences, chair of the Emerging Companies Section of the Biotechnology Innovation Organization, and a board member of Galapagos NV and the Massachusetts Eye and Ear Institute.
Bosley is a graduate of Cornell University, where she received a BA as a college scholar.
About the Series
The Joseph Priestley Society (JPS) promotes a deeper understanding of science, technology, and industry, with an emphasis on innovation and entrepreneurship. Speakers are leaders from a wide variety of large and small chemical companies and the financial, consulting, and academic communities.
The Ralph Connor Memorial Lecture was created by the Science History Institute to showcase periodic addresses on the role of research in the development of technology and industry by eminent practitioners in the chemical and molecular sciences.
For more information about this event, please contact Sarah Reisert at 215.873.8263 or email@example.com.